, Tracking Stock Market Picks
Enter Symbol:
Spectrum Pharmaceuticals, Inc. (SPPI) [hlAlert]

up 8.54 %

Spectrum Pharmaceuticals, Inc. (SPPI) rated Sell with price target $5.50 by WallachBeth

Posted on: Wednesday,  Mar 13, 2013  8:25 AM ET by WallachBeth

WallachBeth rated Sell Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) on 03/13/2013, when the stock price was $8.13. Since
then, Spectrum Pharmaceuticals, Inc. has lost 7.87% as of 12/04/2015's recent price of $7.49.
If you would have followed this WallachBeth's recommendation on SPPI, you would have gained 8.54% of your investment in 996 days.

Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company?s product is apaziquone (formerly EOquin), which is in two Phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix is in a Phase 2 clinical trial for benign prostatic hypertrophy (BPH). On December 15, 2008, Spectrum and Cell Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT Oncology, LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology, LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/13/2013 8:25 AM Sell
8.13 5.50
as of 12/13/2013
1 Week up  3.38 %
1 Month up  1.93 %
3 Months down  -13.71 %
1 YTD down  -12.17 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy